AbCellera Biologics (ABCL) Free Cash Flow: 2020-2025
Historic Free Cash Flow for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to -$61.5 million.
- AbCellera Biologics' Free Cash Flow fell 29.80% to -$61.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$153.1 million, marking a year-over-year increase of 22.42%. This contributed to the annual value of -$187.0 million for FY2024, which is 54.73% down from last year.
- AbCellera Biologics' Free Cash Flow amounted to -$61.5 million in Q3 2025, which was down 34.42% from -$45.8 million recorded in Q2 2025.
- In the past 5 years, AbCellera Biologics' Free Cash Flow ranged from a high of $241.7 million in Q2 2022 and a low of -$139.3 million during Q3 2022.
- In the last 3 years, AbCellera Biologics' Free Cash Flow had a median value of -$45.8 million in 2025 and averaged -$39.8 million.
- The largest annual percentage gain for AbCellera Biologics' Free Cash Flow in the last 5 years was 7,961.99% (2021), contrasted with its biggest fall of 11,570.54% (2021).
- Over the past 5 years, AbCellera Biologics' Free Cash Flow (Quarterly) stood at -$26.1 million in 2021, then skyrocketed by 171.08% to $18.6 million in 2022, then plummeted by 283.20% to -$34.0 million in 2023, then spiked by 30.59% to -$23.6 million in 2024, then declined by 29.80% to -$61.5 million in 2025.
- Its Free Cash Flow was -$61.5 million in Q3 2025, compared to -$45.8 million in Q2 2025 and -$22.2 million in Q1 2025.